the risk of eGFR slope confirmation is not insignificant. The first interim results we need to prove what was done in P2 on a bigger group. Then around December we need to prove something that Travere failed to and we haven’t yet.
my hunch is once this endpoint is confirmed the flood gates will truly be opened. But until then there’s going to be some market hesitation.
now, a US / China licensing agreement may blow that out of the water but imo that’s where we are at
Dimerix (ASX: DXB) Discussion Thread, page-5
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.035(7.22%) |
Mkt cap ! $247.5M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 48.5¢ | 44.5¢ | $1.897M | 4.104M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 79166 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 103477 | 2 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |